gvtcx

Supply of Plasmids and Synthetic DNA for Viral Vector Manufacture

NHS Blood and Transplant Published 13 Aug 2025 Find a Tender
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£7,200,000 (£8,640,000 inc. VAT)
Statusplanning
Category (CPV) 33698000
RegionSouth West
OCIDocds-h6vhtk-0586a2

description

As part of a preliminary market engagement exercise, NHS Blood & Transplant (NHSBT) are seeking to engage with suppliers of nucleic acids including plasmid DNA; synthetically produced DNA and/or enzymatically produced DNA. The intended use of the nucleic acids by NHSBT includes: a) the GMP grade production of gene therapy vectors such as lentiviral, adeno-associated viral vectors and novel gene therapy vectors, for clinical trials and commercial production where applicable; b) gene therapy vectors suitable for pre-clinical studies, such as toxicology and biodistribution studies and gene therapy vectors suitable for R&D purposes.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
13 Aug 2025 Preliminary market engagement (UK2) Procurement Act 2023 048226-2025

more from NHS Blood and Transplant

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.